Skip to the content
logo mainlogo darklogo light
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers
logo mainlogo darklogo light
HomePosted by Edison Oncology(Page 2)
Presentations and Publications

EO1001: A first-in-class irreversible pan-ErbB inhibitor with excellent brain penetration

Edison Oncology
January 4, 2020
Presentations and Publications

Preclinical development of EO1001, a novel irreversible brain penetrating pan-ErbB inhibitor (Oral Presentation)

Edison Oncology
August 4, 2019

Posts pagination

1 2
Recent Updates

Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers

Edison Oncology
April 8, 2024

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting

Edison Oncology
April 20, 2023
Categories
News Presentations and Publications Press Release
w
Contact us today
View more

Company

  • Leadership Team
  • About
  • Careers

Information

  • Technology
  • Product Pipeline
  • Press Releases

Menlo Park, CA

  • 3475 Edison Way,
    Suite R
    Menlo Park, CA 94025

© 2025 Edison Oncology, All Rights Reserved

Back to top Drag
  • 01About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • 02Technology
  • 03Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • 04News & Media
    • Press Releases
    • Presentations & Publications
  • 05Contact
  • 06Careers